CDK2 and cancer: Tetrandrine is used as a potential CDKs inhibitor that directly inhibits CDK4, CDK2-CycE to arrest the cell cycle in the G1/S phase [15,16,17], and then the effects of tetrandrine on controlling the cancer-associated gene (GAGE) expression are able to activate the apoptosis and autophagy pathway in cancer cells [18,19,20].